Novo Nordisk shares plunge 23% after Wegovy maker names new CEO, cuts full-year guidance
The company said the lower outlook was driven by weaker second-half U.S. sales growth forecasts for its Wegovy weight loss drug and Ozempic diabetes treatment.
The company also named Maziar Mike Doustdar as its new CEO after the surprise ousting of Lars Fruergaard Jørgensen in May.
Shares fell as much as 26% before paring losses slightly.
Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.
Nurphoto | Nurphoto | Getty Images
Danish pharmaceutical giant Novo Nordisk on Tuesday named its new CEO while simultaneously slashing its full-year guidance, citing weaker growth expectations for its blockbuster Wegovy obesity drug in the key U.S. market.
The drug maker said company veteran Maziar Mike Doustdar would take over as president and CEO following the surprise ousting in May of Lars Fruergaard Jørgensen. The appointment is effective Aug. 7.
Shares fell as much as 26% before paring losses slightly to close down 23% by 4:30 p.m. London time (11:26 a.m. ET).
The company said it now expects full-year sales growth of 8% to 14% at constant exchange rates, down from a prior target of 13% to 21%.
It expects annual operating profit growth of 10% to 16% versus the previously estimated target of 16% to 24%, also at constant exchange rates.
Novo Nordisk said Tuesday that the lower outlook was driven by weaker second-half U.S. sales growth forecasts for its Wegovy weight-loss drug and Ozempic diabetes treatment.
"For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition," it added in a statement.
Novo Nordisk.
It comes after the company previously downgraded its 2025 outlook in May, as it reported lower-than-expected first-quarter sales. The company is due to report its full second-quarter sales on Aug. 6.
Doustdar, who joined Novo Nordisk in 1992, has held several executive functions across Europe and Asia, serving most recently as executive vice president of international operations.
In a statement accompanying the announcement, chairman Helge Lund described Mike Doustdar as "the best person to lead Novo Nordisk through its next growth phase."
"I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need," Doustdar added.
The Copenhagen-headquartered pharma giant has been battling softer U.S. Wegovy sales as competition from compounded drug makers ramped up in the wake of a Food and Drug Administration drug shortage ruling.
Its share price has shed over 42% this year.
It nevertheless previously said that it expected those pressures to ease in the second half of the year as the availability of copycat drugs was phased out.
Meantime, the firm has struggled to shake negative sentiment following a series of disappointing trial results for its next-generation obesity drug candidate CagriSema amid increased market competition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
3 hours ago
- The Hill
Americans' becoming more aware of GLP-1 drugs like Ozempic, Wegovy: Survey
The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped significantly in the last few years, a new survey shows. The YouGov poll, released Friday, shows that at least 80 percent of respondents have heard at least 'a little bit' about semaglutide, a medication used to treat Type 2 diabetes that also helps a user to shed weight. In March 2023, only 60 percent of Americans were aware of the drug. A year later, in March 2024, that number had jumped to 70 percent, the pollster noted. The latest survey also shows that the share of those who have heard 'a lot' about the medication has nearly doubled since 2023, increasing to 41 percent from 23 percent. Just 36 percent of respondents say they know someone who has taken semaglutide. Around 14 percent listed a family member took the medicine, 16 percent named a friend, 11 percent identified an acquaintance and 7 percent said they had taken it themselves, according to the poll. Several also noted they knew a user in more than one category. Women are more likely than men, 43 percent to 29 percent, to know someone — including themselves — who has taken a GLP-1 agonist drug, per the survey. The weight loss medications — including Wegovy, Ozempic, Zepbound and others — have been available since 2005 but have only in the past few years been used to treat obesity. The drugs work by mimicking a hormone in the body — glucagon-like peptide-1 — that stimulates insulin secretion and reduces appetite. Possible side effects of taking the medication include nausea, diarrhea, vomiting, and constipation. While semaglutide is currently only prescribed for weight loss or treating diabetes, early research is pointing to possible benefits for a host of other issues, including treatment for addiction, neurodegenerative diseases and conditions that affect the heart, kidney or liver. The latest survey found that roughly a quarter of respondents said they would be 'very' or 'somewhat' interested in taking the medication as a weight loss treatment. About a third of Americans have either taken the drug or said they would be interested in trying it. On the other side, about 17 percent said they were 'not very' interested in the medication and 45 percent signaled they were not at all interested. A separate poll from last September found that around a quarter of adults in the U.S. would consider using weight loss medications without consulting their doctor. The YouGov analysis is based on an online survey conducted from May 22-25 among 1,109 adults in the U.S. The margin of error for the full sample is 4 percentage points.
Miami Herald
7 hours ago
- Miami Herald
Craft beer is dying, but this brewer is bucking the trend
Craft beer is in decline. For the first time in nearly two decades in the U.S., more breweries closed in 2024 than opened, according to the Brewers Association. But one brand, Dogfish Head Brewery, is celebrating its 30th anniversary and bucking the trend, expanding its business and staying relevant while others close their doors. Don't miss the move: SIGN UP for TheStreet's FREE Daily newsletter Part of the decline is a hangover from the pandemic shutdowns, which hit restaurants and breweries hard. Even as pandemic restrictions lifted, breweries found themselves in an altered landscape. Many didn't survive. The ones that did faced a new set of challenges. At the top of the list: rising rents and labor costs, supply chain disruptions, and inflation on ingredients and packaging. Then came tariffs, affecting brewing equipment, steel kegs, and aluminum cans. These headwinds made the financial pressures facing many brewers impossible to overcome. Image Source: Bloomberg/Getty Images The entire alcoholic beverage industry has been facing an existential problem: changing consumer behavior. Americans are drinking less beer, particularly younger consumers, who are opting instead for hard seltzers, canned cocktails, nonalcoholic drinks - or skipping alcohol altogether. Recreational cannabis is now legal in 24 states, which is also taking a bite (sip?) out of the market. Then there is the growing use of Wegovy, Zepbound, and Mounjaro, drugs that curb appetite and often reduce alcohol cravings. Related: Beloved brewery faces Chapter 11 bankruptcy, asks for help Amid this perfect storm, Dogfish Head Brewery stands out as an exception - and a blueprint for resilience. The Delaware-based craft brewer is marking its 30th anniversary in 2025 with continued growth and a broader business model that's helping it weather the industry downturn. "Weed, wellness, and weight-loss drugs are all impacting the way people drink," Dogfish Head Brewery founder Sam Calagione told TheStreet in an exclusive interview. "Instead of fighting that, we've expanded the portfolio to meet people where they are." When Dogfish Head founders Mariah and Sam Calagione started making beer for their Delaware restaurant in 1995, they had no idea they were at the forefront of a new industry; twenty years in, Dogfish Head Brewery's sales were reportedly between $110 and $120 million. Then, in 2019, Dogfish Head announced it was merging with The Boston Beer Company, bringing the country's second-largest craft brewer (Boston Beer, maker of Samuel Adams) together with the 13th largest, Dogfish Head. The merger was massive, but it preserved the independent craft brewery status of both brands, as defined by the Brewers Association. Related: Another popular beer and brewery brand files Chapter 11 bankruptcy The Boston Brewing Company acquisition was worth around $300 million in cash and stock to the Calagiones. Following the merger, Calagione joined Boston Beer's board of directors, and he and his wife Mariah are the company's largest individual shareholders outside of Jim Koch, founder and chairman of The Boston Beer Company. Today, Dogfish Head's portion of the Boston Beer Company's sales is around $275 million (out of a total $2.01 billion), according to RocketReach. So what's Dogfish Head's secret? There's more than one. First, Dogfish Head has been making ready-to-drink canned beverages almost since day one. The company distills its own Dogfish Head spirits, including vodka ("Awe-Spray"), gin ("Compelling"), and rum ("Barrel Honey") for use in its Vodka Lemonade, Vodka Mule, and Rum Mai Ta, among other drinks. Dogfish Head's business model, which Calagione calls "beyond beer," isn't limited to just beverages. The company operates a boutique hotel in Lewes, Delaware, as well as brewery and distillery tours that he says draw hundreds of thousands of visitors annually. Retail closings: Popular retail chain to close unprofitable store locationsBankrupt retail chain unloads store leases, key assetPopular discount retailer files bankruptcy, closes all stores This hospitality component adds a revenue stream independent of distribution or retail, and gives the brand a valuable experiential marketing engine. Visitors become loyal customers, and the tours reinforce Dogfish Head's position as a craft pioneer. That kind of vertical integration - product, experience, and lifestyle brand - is a key differentiator in an otherwise saturated industry. Dogfish Head has always been known for its off-centered ales, using unexpected ingredients – from black limes and saffron to Mace and even human saliva – to create bold flavors. One of its earliest successes was Midas Touch, a beer brewed with honey, white Muscat grapes, and saffron, inspired by an ancient recipe found in a 2,700-year-old drinking vessel from King Midas' tomb. The company's bestselling beer today is its 60 Minute IPA, which Calagione says gives him inspiration even as he rethinks his own drinking. "I spend 60 minutes every day on a paddle board or my mountain bike out in the bounty of Mother Nature," he says. "I do that to earn my beer calories for the evening." When Dogfish Head Brewery was founded, Calagione says there were 600 craft brewers in the U.S. Today, there are around 10,000, so there is a lot of competition to fend off, but Dogfish Head is a model showing how craft breweries can evolve into multi-channel businesses that go beyond beer. "Short term we're facing some challenging trends, but we need to remember beer's been around and part of human community building for 10,000 years," he said. "There are a lot of closings and bankruptcies and sad stories," Calagione said. "So we're really excited to tell the story of how we're bucking those trends." Related: Popular Off the Las Vegas Strip casino bar closing The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
7 hours ago
- Yahoo
Getty Images Holdings (GETY) – Shutterstock Merger Inches Closer
Getty Images Holdings, Inc. (NYSE:GETY) is . On June 10, the company received a significant boost on its proposed merger with Shutterstock, a leading provider of high-quality creative content for transformative brands. Shutterstock's stockholders approved the adoption of the proposed merger, with approximately 82% of the issued and outstanding shares voting in favor. The approval paves the way for the merger of the two companies, which is expected to result in a combined company capable of meeting the ever-changing needs of customers through investments in content creation, event coverage, and technological innovation. 'Our complementary strengths will allow us to better serve customers while also delivering exceptional value to our partners, contributors and stockholders in a fast evolving and competitive environment,' said Paul Hennessy, Shutterstock's Chief Executive Officer. The merger between Getty Images and Shutterstock is expected to close in the second half of the year, subject to regulatory approvals. Getty Images Holdings, Inc. (NYSE:GETY) is a communication services company that provides creative and editorial visual content solutions. It offers creative content, including royalty-free photos, illustrations, vectors, videos, and generative AI services, as well as editorial content, which consists of photos and videos. While we acknowledge the potential of GETY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
